Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent

25-May-2012 - USA

Alnylam Pharmaceuticals, Inc. and Plant Bioscience Limited (PBL) announced  that they have entered into a licensing agreement.  PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (U.S. Patent No. 8,097,710) for use in the field of human therapeutics.  Financial terms were not disclosed.

“We are pleased to expand our leading IP estate with a license to the Baulcombe patent,” said Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer of Alnylam.  “Alnylam continues to leverage its patent estate for the advancement of innovative medicines to patients and to enable the entire RNAi therapeutics field, with over 30 license agreements formed to date.”

U.S. Patent No. 8,097,710 issued in January 2012, and is the most recently issued patent in PBL’s IP estate in short RNAs derived from the seminal work of Prof David Baulcombe and Dr Andrew Hamilton, at The Sainsbury Laboratory (Norwich, UK).

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances